• Trelagliptin Enhances Osteoblastic Differentiation via RUNX2

  2026-05-15

  This study demonstrates that trelagliptin, a DPP-4 inhibitor, significantly promotes osteoblastic differentiation in MC3T3-E1 cells through upregulation of RUNX2 and activation of AMPK signaling. These findings suggest a potential new therapeutic avenue for osteoporosis management beyond glycemic control.

• CGRP–RAMP1 Axis Regulates CD4+ T Cells and Allergic Response

  2026-05-15

  This study uncovers the role of the neuropeptide CGRP and its receptor RAMP1 in restraining CD4+ T cell activation during allergic sensitization. By integrating advanced in vivo and molecular techniques, the authors delineate a neuroimmune pathway that limits allergic asthma, offering mechanistic insights for immune modulation strategies.

• Asunaprevir (BMS-650032): Uncovering Genotype-Spanning HCV I

  2026-05-14

  Explore how Asunaprevir (BMS-650032) achieves broad-spectrum HCV RNA replication inhibition through precise NS3/4A targeting. This article uniquely dissects genotype-spanning mechanisms and offers advanced, protocol-level guidance for antiviral assay innovation.

• Nintedanib (BIBF 1120): Strategic Leverage in Translational

  2026-05-14

  This thought-leadership article examines Nintedanib (BIBF 1120), a triple angiokinase inhibitor, through the lens of mechanistic insight and translational research strategy. Integrating recent findings on ATRX-deficient glioma sensitivity, validated protocols, and evolving clinical contexts, it provides actionable guidance for cancer and fibrosis researchers. The article differentiates itself from standard product pages by bridging biological rationale with workflow integration and foresight on future research opportunities.

• Tofacitinib Repairs Inflammatory and Metabolic Defects in RA

  2026-05-13

  This study reveals that tofacitinib (CP-690550) reverses inflammation and mitochondrial dysfunction in GM-CSF-driven rheumatoid arthritis (RA) macrophages by targeting STAT5 signaling and metabolic pathways. These findings highlight a mechanistically distinct approach to attenuate RA pathology where conventional cytokine and metabolic interventions fall short.

• Resveratrol Suppresses CAF-Mediated Breast Cancer Organoid G

  2026-05-13

  This study establishes a co-culture model of breast cancer organoids and cancer-associated fibroblasts (CAFs) to rigorously evaluate resveratrol's effects on tumor growth and CAF-mediated protection. The findings reveal that resveratrol not only inhibits organoid proliferation but also downregulates VCAN and TGF-β expression in CAFs, highlighting its potential to overcome microenvironment-driven drug resistance.

• Red Blood Cell Lysis Buffer: Optimizing Erythrocyte Removal

  2026-05-12

  Red Blood Cell Lysis Buffer empowers researchers to efficiently eliminate erythrocytes while preserving nucleated cells for flow cytometry and molecular analysis. This article delivers protocol refinements, troubleshooting strategies, and cross-study insights that transform routine blood sample preparation into reproducible, high-impact experimental pipelines.

• Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO): Technica

  2026-05-12

  Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) addresses the challenge of protein degradation during cell and tissue extraction, enabling reliable downstream proteomics, especially mass spectrometry workflows. It should be used where broad-spectrum protease inhibition is needed without introducing MS artifacts, but is not appropriate for workflows requiring AEBSF or where DMSO incompatibility is a concern.

• DOT1L Inhibition: Mechanistic Leverage and Translational Fro

  2026-05-11

  A thought-leadership article examining the mechanistic underpinnings and translational opportunities of DOT1L inhibition, with a focus on EPZ5676. The piece navigates recent advances linking DOT1L to innate immunity, MLL-rearranged leukemia, and fibrotic disease, critically appraising evidence, experimental protocols, and future directions for translational researchers.

• Sulfamonomethoxine: Environmental Biotransformation and Assa

  2026-05-11

  Explore Sulfamonomethoxine's unique role as a broad-spectrum sulfonamide antibiotic in environmental biotransformation, veterinary, and aquaculture assays. This in-depth analysis highlights scientific insights and practical assay guidance, setting it apart from existing resources.

• Elobixibat Hydrate: Advancing Therapy for Chronic Constipati

  2026-05-10

  This review by Acosta and Camilleri provides a mechanistic and clinical evaluation of elobixibat hydrate, a selective ileal bile acid transporter inhibitor, in managing chronic idiopathic constipation. By targeting enterohepatic bile acid circulation, elobixibat offers a novel approach to augmenting colonic motility, with minimal adverse effects and implications for metabolic comorbidities.

• CUDC-907: Technical Guidance for Dual PI3K and HDAC Inhibiti

  2026-05-09

  CUDC-907 provides a dual PI3K and HDAC inhibitor for researchers modeling cancer cell signaling, cell cycle, and apoptosis in vitro. It is optimized for controlled laboratory workflows and should not be used in diagnostic or clinical applications.

• Firefly Luciferase mRNA (ARCA, 5-moUTP): Structure, Evidence

  2026-05-09

  Firefly Luciferase mRNA (ARCA, 5-moUTP) is a chemically optimized bioluminescent reporter mRNA. Its ARCA cap and 5-methoxyuridine modifications increase translation and stability, delivering robust, reproducible signals in gene expression assays. This dossier details its molecular rationale, mechanism, and benchmarked performance.

• Indazole/Indole Glucagon Receptor Antagonists for Diabetes:

  2026-05-08

  This study introduces a new series of indazole- and indole-based glucagon receptor antagonists with potent in vitro and in vivo efficacy for type 2 diabetes models. Through targeted structural modifications, the research demonstrates improved oral activity and performance benchmarks relative to established antagonists like MK 0893, informing selection and optimization of GCGR inhibitors for metabolic research.

• Prostaglandin E2: Experimental Strategies for Inflammation R

  2026-05-07

  Prostaglandin E2 (PGE2) enables reproducible inflammation and immune modulation assays, streamlining workflows from cell models to translational studies. Discover how APExBIO’s PGE2 empowers advanced applications, troubleshooting, and protocol optimization in inflammation research and beyond.

450 records 18/30 page Previous Next First page 上5页 1617181920 下5页 Last page